Table 1.
BPD Prevention Methods | |
---|---|
Antenatal glucocorticoids | Given to women between 23 and 34 WG Less respiratory distress syndrome Shorter periods of mechanical ventilation and oxygen supplementation [120] |
Surfactant | Reduces the need for mechanical ventilation and oxygen dependence [121] |
LISA technique [122] | Reduces the need for mechanical ventilation [123,124] |
Protective ventilation |
Low tidal volumes Early weaning from mechanical ventilation Early CPAP and noninvasive ventilation |
Targeted O2 saturation |
Reducesoxidative damage [125] |
Early therapy with caffeine | Shorter time on ventilatory support [126] Better lung function [127,128] Modulates angiogenic gene expression early in lung development [129] |
Vitamin A | Has a role in lung maturation and repair Reduces the development of BPD at 36 weeks PMA, but has no effect on long-term respiratory morbidity [130,131,132,133,134,135] |
Postnatal infection control |
Reduces inflammatory mediators and the need for mechanical ventilation |
Hemodynamically significant PDA treatment | Reduces pulmonary overflow, and this limits the need for ventilation [136] |
Fluid restriction | Prevents pulmonary overflow and consequent lung edema Reduces the incidence of PDA [137] |
Azithromycin prophylaxis | In newborns colonized with Urea plasma [138] |
Nutrition | Adequate enteral supplement of nutrients [139] Possibly with mother’s own milk [140,141] To ensure a good weight gain [142] L-citrulline in particular seems to correlate with a lower incidence of Pulmonary hypertension [143,144] (an interesting trial [NCT03542812] is ongoing) |
Postnatal systemic glucocorticoids | Reduce inflammation, vascular permeability and lung edema Their short- and long-term adverse effects suggest caution in their routine use for preventing BPD [145] |